Latest Commercialisation News

Rent.com.au Limited reported a $3.69 million net loss for FY25 amid modest revenue growth, while securing significant funding to scale its RentBond® product and reshaping its leadership team.

Clean TeQ Water Limited reported a reduced loss of $2.8 million for FY25 and increased its stake in Go2Lithium Inc to 60%, marking a strategic shift as it advances water treatment and critical metals recovery projects worldwide.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

Bisalloy Steel Group Limited reported a 24.4% rise in profit after tax to $19.6 million for FY25, driven by strong Armour & Protection steel sales and international growth. The company declared a 16.5 cents per share fully franked final dividend, up 43.5% from last year, while advancing key growth initiatives in Asia and sensor technology.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.

Cue Energy Resources reports stable 2P reserves of 5.5 million barrels of oil equivalent as of July 2025, balancing improved output in Sampang with declines in Oyong and Wortel fields. Contingent resources also grew, highlighting potential future upside.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.